26 results about "Ginsenoside Rh2" patented technology

The invention discloses a method for generating rare ginsenoside Rh2, which comprises the following steps: adding common glycol type ginsenoside into aspergillus brazilis fermentation liquor for fermentation, and sterilizing after fermentation to obtain a fermentation product; and carrying out enzymolysis by using beta-glucanase and pectinase, and carrying out enzyme deactivation after the enzymolysis is finished, so as to obtain the rare ginsenoside Rh2. The invention also provides the rare ginsenoside Rh2 prepared by the method and application of the rare ginsenoside Rh2. The common glycol type ginsenoside is efficiently and quickly converted into the rare ginsenoside Rh2 through the synergistic interaction of the aspergillus brazilis, the beta-glucanase and the pectinase; the rare ginsenoside Rh2 has the advantages of being simple in preparation method, easy to implement, low in cost, environmentally friendly, free of pollution and the like, and the generated rare ginsenoside Rh2 shows excellent skin care and repairing effects and has wide market prospects when applied to cosmetics.

The present application relates to a kind of multifunctional saponins molecularly imprinted polymer template molecule, molecularly imprinted polymer and its application, belong to plant component refining technical field.The molecularly imprinted polymer of the present application uses virtual template molecule, the template molecule contains hydrogen bond donor and strong electronic effect, it has good adsorption performance to natural saponins compound molecules such as Jiumu saponin AIII, Jiumu saponin BII, Jiumu saponin BIII, Sanqi saponin R1, ginsenoside Rg1, ginsenoside Rg3, ginsenoside Rh2, Tribulus saponin K, Tribulus saponin D, Platanus orientalis saponin D, Shandeng saponin B, Chonglou saponin I, Chonglou saponin II, Chonglou saponin VI.The virtual template molecule is low in cost, can be used for the large-scale preparation of molecularly imprinted polymer, significantly reduces the extraction cost of natural saponins compound.

The invention discloses a method for biosynthesizing ginsenoside by taking tobacco BY-2 cells as a chassis, and belongs to the technical field of bioengineering. The method comprises the following steps that firstly, a recombinant expression vector containing a ginsenoside synthesis pathway key gene set is constructed, and the gene set comprises genes such as tHMGR, SE and SS from ginseng and Pn1-31 and Pn3-31 genes from panax notoginseng; secondly, introducing the recombinant vector into tobacco BY-2 cells, and screening through a solid culture medium to obtain a pure positive cell line; and finally, culturing the positive cell line in a liquid or solid culture medium to obtain ginsenoside Rh2 and / or Rg3. By utilizing the advantages of fast growth and stable culture of the tobacco BY-2 cells, a rare ginsenoside synthesis pathway is successfully reconstructed, efficient heterologous synthesis of the rare ginsenoside is realized, and a repeatable technical scheme is provided for industrial production of the rare ginsenoside.

The application discloses a method for biosynthesizing ginsenoside by using tobacco BY-2 cells as a chassis, and belongs to the technical field of bioengineering. The method comprises the following steps: firstly, a recombinant expression vector containing a key gene set of a ginsenoside synthesis pathway is constructed, wherein the gene set comprises tHMGR, SE, SS and other genes derived from Panax ginseng and Pn1-31 and Pn3-31 genes derived from Panax notoginseng; secondly, the recombinant vector is introduced into tobacco BY-2 cells, and a pure positive cell line is obtained through solid culture medium screening; finally, the positive cell line is cultured in liquid or solid culture medium to obtain ginsenoside Rh2 and / or Rg3. The application successfully reconfigures a rare ginsenoside synthesis pathway by taking advantage of the fast growth and stable culture of tobacco BY-2 cells, realizes efficient heterologous synthesis of the rare ginsenoside, and provides a repeatable technical scheme for industrial production of the rare ginsenoside.

The invention belongs to the technical field of biology and new medicine, and discloses a preparation method of acoustic resonance driven glycyrrhizic acid nano-composite responsive gel, glycyrrhizic acid is used as a drug carrying system, berberine, ursolic acid, baicalein, luteolinin, curcumin, baicalin or ginsenoside Rh2 is used as a water-insoluble natural small molecule drug, and the acoustic resonance driven glycyrrhizic acid nano-composite responsive gel is prepared. Glycyrrhizic acid is an amphiphilic compound composed of one molecule of glycyrrhetinic acid and two molecules of glucuronic acid, a hydrophobic cavity can be formed in a water environment to wrap the water-insoluble natural small molecule medicine, a glycyrrhizic acid nano-composite solution is formed, and meanwhile the solubility of the water-insoluble natural small molecule medicine such as baicalein is improved.

The invention relates to the technical field of skin repair. The invention aims to provide an anti-aging composition with enhanced NK cell activity. The anti-aging composition comprises a utility component and an auxiliary material component for regulating physical properties of the anti-aging composition, the effective component is prepared from the following raw materials in parts by weight: 1 to 2 parts of palmitoyl pentapeptide-4, 1 to 2 parts of acetyl hexapeptide-8, 3 to 5 parts of ginsenoside Rh2, 10 to 15 parts of curcumin, 0.5 part of interleukin-2, 10 to 15 parts of antioxidant and 10 to 15 parts of humectant. According to the anti-aging composition disclosed by the invention, all the components are reasonably proportioned, so that the activity of NK (Natural Killer) cells can be enhanced, and the anti-aging composition has multiple anti-aging effects of resisting wrinkles, resisting oxidation, preserving moisture, regulating immunity and the like.

The invention relates to a novel method for reducing drug-induced cell death, and belongs to the technical field of biological medicines. LP-Rh2 in the form of lipidosome is prepared by providing a skeleton structure by lipidosome and taking ginsenoside Rh2 as a functional component, and after LP-Rh2 and other drugs are jointly added into a cell culture system, the drug-induced cytotoxicity can be inhibited in various scenes, the cell viability is improved, and the drug-induced cytotoxicity can be inhibited. Therefore, the action mechanism of other candidate drugs with cytotoxicity can be better matched and researched in scientific research application, and potential safety risks possibly brought by drugs, especially vaccine adjuvants, can be reduced in drug application.

This patent application discloses a method for preparing ginsenoside Rh2 by bioenzymatic conversion. The method includes using a glycosidase composition derived from Aminobacter sp. Gsoil204 bacteria (GenBank: AGA60126.1) and a β-glycosidase derived from Sphingopyxis alaskensis RB2256 bacteria (GenBank: ABF52736.1) to catalyze the reaction of ginsenoside Rb1, and convert it into ginsenoside Rh2 in a reaction system. After the reaction, the content of ginsenoside Rh2 reaches 36% and the conversion rate reaches more than 60%. The generated enzyme-catalyzed product has a relatively simple composition, is simple to operate, is easy to scale up production, and has broad application prospects.

The application provides a method for simultaneously enriching rare ginsenosides by co-fermentation of Eurotium cristatum and Panax ginseng and a fermentation product, wherein the Eurotium cristatum is inoculated into a fermentation substrate containing the root of Panax ginseng, and solid fermentation is carried out; the fermentation product contains ginsenosides Rg2, Rg3 and Rh2; the contents of the three rare ginsenosides Rg2, Rg3 and Rh2 in the fermented Panax ginseng raw material are simultaneously improved; the content of Rg2 ginsenoside is increased to about 1.7 times of the original content; the content of Rg3 ginsenoside is increased to about 1.7 times of the original content; and a new ginsenoside Rh2 is obtained, so that the nutritional value and medicinal efficacy of Panax ginseng are increased.

The invention provides a strain of P.adami Sys-Gs-003 for producing ginsenoside Rh2, the strain is preserved in the China Center for Type Culture Collection, the preservation date is December 4, 2025, the preservation number is CCTCC NO: M20252779, the preservation number is CCTCC NO: M20252779, the preservation number is CCTCC NO: M2025279, and the preservation number is CCTCC NO: M2025279. The 16S rDNA (ribosomal deoxyribonucleic acid) sequence of the strain is as shown in SEQ ID NO. 1. The Prussella adamsii Sys-Gs-003 strain provided by the invention can produce ginsenoside Rh2 through metabolism, can be subjected to large-scale fermentation culture in a short time, is relatively low in fermentation cost, is not limited by conditions such as time domain, season and the like, and has remarkable advantages. Meanwhile, the invention also provides optimized microbial fermentation conditions and a formula of the culture medium, and the yield of the ginsenoside Rh2 is relatively high.

The present invention belongs to the field of enzyme genetic engineering and biotechnology, and discloses a glycosyltransferase Pq3-O-UGT2 mutant that produces a high yield of rare ginsenoside Rg3, the amino acid sequence of which is any one of the following: the amino acid sequence shown in SEQ ID NO.2, SEQ ID NO.3, and an amino acid sequence with a degree of identity of 50% or more to the amino acid sequence shown in SEQ ID NO.2, SEQ ID NO.3. The mutant of the present invention reduces the conversion efficiency of the original Pq3-O-UGT2 enzyme to ginsenoside F2 and improves the conversion efficiency to ginsenoside Rh2. That is, the reaction of adding a No. 2 glucose group to the C-2 hydroxyl group of the C3-O-glucose group of the ginsenoside Rh2 substrate is improved, catalyzing the production of a high-medicinal-value product, the rare ginsenoside Rg3, thereby improving the efficiency and selectivity of the enzymatic synthesis of the rare ginsenoside Rg3.

The invention discloses a culture method and application of high-secretion IFN-gamma CD4 + T cells, and relates to the technical field of immune cell culture. The cell culture medium disclosed by the invention is prepared from the following components: IL-2, IL-7, IL-15, IL-18, AB plasma, ConA, OKT3, CD28, an STING agonist, astragaloside, ginsenoside Rh2 and astragalus polysaccharide. The CD4 + T cells cultured by the culture medium disclosed by the invention are cultured in vitro for 15 days, the content of the CD4 + T cells is greater than 70%, and the CD4 + T cells secrete IFN-gamma at a higher level compared with the CD4 + T cells cultured by a common CD4 + T cell culture medium, and in addition, the in-vitro killing rate of the CD4 + T cells to HCT116 intestinal cancer cells reaches 95% or above due to the added STING agonist, astragaloside, ginsenoside Rh2 and astragalus polysaccharide.

The invention discloses a glycosyl transferase mutant, and belongs to the technical field of gene engineering and enzyme engineering. According to the invention, O-glycosyl transferase UGT73F13 in a wild type UGT73 family derived from Glycyrrhiza uralensis (Glycyrrhiza uralensis) is subjected to semi-rational design mutation from outside to inside, and an excellent amino acid mutant is screened out. The multi-site mutant of the novel O-glycosyl transferase contains five mutants, wherein V403 is mutated into S, C274 is mutated into T, C269 is mutated into N, S87 is mutated into A, and L84 is mutated into T. The catalytic efficiency of the obtained novel mutant is improved by 9.29 times compared with that of a wild type, the thermal stability (T1 / 2 value) is improved by 8.4 times, the substrate conversion rate of protopanoxadiol (PPD) is greater than or equal to 95%, and the C-3 hydroxyl glycosylation specificity reaches 100%. The invention provides a unique biocatalyst and a conversion process for the preparation of 20 (S)-ginsenoside Rh2 with high added value.

This invention discloses a method for generating rare ginsenoside Rh2, comprising the following steps: adding common diol-type ginsenosides to Aspergillus brasiliensis fermentation broth for fermentation, sterilizing after fermentation to obtain the fermentation product; then enzymatically hydrolyzing with β-glucanase and pectinase, and inactivating the enzymes after hydrolysis to obtain rare ginsenoside Rh2. This invention also provides the rare ginsenoside Rh2 obtained by this method and its applications. This invention utilizes the synergistic effect of Aspergillus brasiliensis, β-glucanase, and pectinase to efficiently and rapidly convert common diol-type ginsenosides into rare ginsenoside Rh2. It has the advantages of simple preparation method, ease of implementation, low cost, and environmental friendliness. The generated rare ginsenoside Rh2 exhibits excellent skin-care and repairing effects and has broad market prospects for application in cosmetics.

The present invention discloses a dammarane-type tetracyclic triterpenoid saponin composition and its application, belonging to the field of biomedicine technology. The present invention combines three saponins (notoginsenoside Ft1, 20(R)-ginsenoside Rh2, and 20(R)-ginsenoside Rg3) to prepare a composition. The composition effectively inhibits the elevation of triglycerides (TG), total cholesterol (TC), malondialdehyde (MDA), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) in the liver of mice in both high-dose (40 mg / kg) and medium-dose (20 mg / kg) groups. It also effectively promotes the synthesis of glutathione (GSH), curbing the weight loss and liver weight gain of mice. The high-dose composition effectively curbs the formation of fat particles in the liver and has a good therapeutic effect on alcoholic fatty liver disease.

The present application provides a ginsenoside-protein peptide complex for nutritional support of cancer patients, and a preparation method and application thereof, and belongs to the technical field of post-chemotherapy nutritional support.The present application comprises ginsenoside Rg3 5-7 parts, ginsenoside Rh2 2-4 parts, Compound K 0.5-1.5 parts, whey protein peptide 80-120 parts, marine fish scale peptide 25-40 parts, beta-glucan 8-12 parts, nano-curcumin 15-25 parts, HMB 20-30 parts, sodium butyrate 35-50 parts, N-acetylcysteine 40-60 parts, vitamin C 40-60 parts, and selenium yeast 0.6-1 part by weight.The present application can play an anti-tumor auxiliary role, provide nutritional support for cancer patients after chemotherapy, reduce the side effects of chemotherapy, and improve the quality of life.

The invention belongs to the technical field of enzyme engineering, and discloses a fusion enzyme for producing rare ginsenoside Rh2 and a preparation method and application thereof. The active part of the fusion enzyme is obtained by sequentially connecting beta-glucosidase Bglpm, a connecting peptide and beta-glucosidase Bgp1. Two enzymes are fused into one enzyme molecule through a gene fusion technology, and the fusion enzyme obtained after screening and optimization effectively improves the catalytic efficiency of the enzyme, so that the reaction rate of converting ginsenoside Rd into rare ginsenoside Rh2 is remarkably improved, the fusion enzyme simplifies the catalytic process, reduces the reaction steps and reaction time, and is suitable for industrial production. And the production efficiency can be improved and the production cost can be reduced.

The invention is suitable for the technical field of biological medicine, and provides a cell microvesicle based on freezing extraction and an extraction method and application thereof, ginsenoside Rh2 is used for pre-stimulating human umbilical cord mesenchymal stem cells (hUC-MSCs), a freezing extraction technology is used for extracting cell-derived frozen microvesicles (CDCs), and the novel engineered vesicles Rh2-CDCs are prepared. The method can effectively improve in-vivo blood coagulation and fibrinolytic system functions, reduce multi-organ injury, improve the treatment effect and improve the biological stability of nano-drug treatment, and the freezing extraction technology not only greatly shortens the extraction time and reduces the production cost, but also can obtain the microvesicles with higher concentration, so that the microvesicles have better application prospects. The technical bottleneck of the traditional exosome in application is expected to be overcome; besides, the freezing extraction technology is also suitable for vesicle extraction of other types of cells, and the extracted CDCs can be used as a nano-particle platform to deliver other drugs and active ingredients, so that the freezing extraction method has a wide application prospect.

The application belongs to the field of drug delivery and particularly relates to a composite porous stent, a composite porous drug delivery system and application. The composite porous stent comprises crosslinked oxidized hyaluronic acid, methacrylated xanthan gum, gelatin and sodium alginate; the composite porous drug delivery system is constructed by loading hyaluronic acid-coated quercetin and ginsenoside Rh2 nanoparticles on the composite porous stent, and can precisely and targetedly deliver the loaded traditional Chinese medicine components to a lesion site, so as to achieve the purpose of high-efficiency, safe and targeted treatment of breast cancer.

The invention discloses a method for converting panoxadiol into ginsenoside Rh2, belongs to the field of natural product chemistry and medicinal chemistry, and particularly relates to a method for converting inactive main components in traditional Chinese medicines into active components. The invention provides a ginseng glycosyl transferase mutant and application thereof. Compared with an amino acid sequence SEQ ID No.1, the amino acid sequence of the mutant is as shown in SEQ ID No.1; in an amino acid sequence SEQ ID No.1, eight sites of S144, Y231, G275, T304, H334, A375, R415, Q445 and the like are respectively subjected to three combined mutations, four combined mutations, four combined mutations, five combined mutations, six combined mutations, seven combined mutations or one of eight combined mutations; the novel ginseng glycosyl transferase mutant industrial enzyme is used for directly converting panaxadiol in ginseng into high-activity ginsenoside Rh2. The ginseng glycosyl transferase mutant enzyme constructed by the invention has the characteristics of low enzyme cost, short conversion time, simple process operation and the like, and has a wide prospect of large-scale industrial application.

The invention belongs to the technical field of traditional Chinese medicine and medical skin care, and discloses a ginseng anti-inflammatory sunscreen repair double-effect skin cream and a preparation method thereof.The skin cream is a cream agent prepared by taking ginseng and liquorice extract as main components of a water phase and almond oil as a main component of an oil phase, the total proportion of the oil phase in a finished product is smaller than or equal to 28%, and the total proportion of the oil phase is smaller than or equal to 25%. The total percentage of the ginseng extract and the licorice extract is less than or equal to 7.5%, and the main components are as follows: the ginseng extract accounts for 3.5-5.5%, and the active component ginsenoside Rh2 + Rg3 is more than or equal to 1.2%; the ratio of the licorice extract is 1.2-2.5%, and the active ingredient dipotassium glycyrrhizinate is greater than or equal to 0.8%; the almond oil is used as an adjuvant drug and a conductant drug and accounts for 12-18%, and the balance is ionized water. Through combination of a traditional Chinese medicine compatibility theory and a preparation process, the problems of single effect, unstable components and the like are solved, and the product has dual effects of sunscreen, light aging resistance and anti-inflammatory repair and breaks through the limit of medical skin care products and treatment drugs.

The application discloses a medicine containing ginsenoside Rh2 in the field of medicine and a preparation method and application thereof in treating kidney diseases, and relates to a medicine containing ginsenoside Rh2 and two novel derivatives of ginsenoside Rh2, one of which is a kidney-targeting prodrug derivative formed by conjugating polyethylene glycol to the glycosyl of saponin through a cleavable linker, and the other is an anti-pyroptosis derivative in which a sulfate group is introduced into the glycosyl of saponin. The preparation method comprises synthesizing the two derivatives respectively, mixing them with the prototype ginsenoside Rh2 and pharmaceutical excipients, dissolving, adjusting the pH value, filtering, sub-packaging and freeze-drying to prepare a freeze-dried powder injection. The medicine composition significantly enhances the anti-inflammatory, cell pyroptosis inhibition and anti-fibrosis effects on kidney diseases through the synergistic effect of multiple active ingredients, improves the water solubility and targeting of the medicine, and provides a new effective scheme for treating chronic kidney diseases such as diabetic nephropathy.

The invention discloses puerarin lipidosome with ginsenoside Rh2 as a lipid membrane material and a preparation method and application of the puerarin lipidosome, the membrane material cholesterol of the lipidosome is replaced with the lipidosome (Rh2-Pue-LP) of ginsenoside Rh2 de-entrapped puerarin, the Rh2-Pue-LP can inhibit and activate a JAK2-STAT3 signal channel, so that transcription of NLRP3 is inhibited, and the lipidosome has the advantages that the lipidosome can be used for preparing the puerarin lipidosome with the ginsenoside Rh2 as the lipid membrane material; the traditional Chinese medicine composition can be used for inhibiting microglial cell activation and neuronal apoptosis, effectively penetrating through a complete blood brain barrier (BBB), reaching a focus part and playing a role in neuroprotection.

The invention provides a composition for adjuvant therapy of tumors as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical compositions. The composition is prepared from the following raw materials in parts by weight: 15 to 25 parts of poria cocos, 15 to 25 parts of semen coicis, 5 to 15 parts of radix angelicae sinensis, 3 to 7 parts of bulbus lilii, 4 to 6 parts of rhizoma anemarrhenae, 4 to 6 parts of pericarpium citri reticulatae, 2 to 4 parts of endothelium corneum gigeriae galli, 4 to 6 parts of rhizoma atractylodis macrocephalae, 3 to 5 parts of liquorice root, 3 to 10 parts of lucid ganoderma, 4 to 7 parts of selenium-enriched cardamine violifolia, 4 to 6 parts of ginseng peptide, 0.005 to 0.01 part of ginsenoside Rg3, 0.005 to 0.01 part of ginsenoside Rh2, 1 to 5 parts of vitamin C and 4 to 6 parts of compound amino acid powder. The composition provided by the invention achieves the effects of adjuvant therapy of tumors and inhibition of postoperative tumor recurrence through multiple ways of improving sleep, enhancing immunity and the like. According to the preparation method disclosed by the invention, the effects of the composition are ensured, and meanwhile, the prepared composition is safe and non-toxic.

The invention provides an enzymolysis rare ginsenoside composition and application of the enzymolysis rare ginsenoside composition in qi and blood tonifying products. The composition comprises ginsenoside and astragalus polysaccharide, the mass ratio of the ginsenoside to the astragalus polysaccharide is (0.5-1.5): 2, the ginsenoside comprises ginsenoside Compound K, ginsenoside Rg3 and ginsenoside Rh2, and the mass ratio of the ginsenoside Compound K to the ginsenoside Rg3 to the ginsenoside Rh2 is (0.8-1.2): (0.8-1.2): 1. The ginsenoside and the astragalus polysaccharide are matched according to a proper proportion, so that a synergistic effect can be achieved in the aspect of tonifying qi and blood, the symptom of deficiency of qi and blood is effectively improved, and the qi and blood tonifying effect of the product is improved.

The invention provides a bacillus cereus Sys-Gs-004 strain for producing ginsenoside Rh2, the strain is preserved in China Center for Type Culture Collection, the preservation date is December 4, 2025, the preservation number is CCTCC NO: M20252780, the preservation number is CCTCC NO: M20252780, the preservation number is CCTCC NO: M20252780, and the preservation number is CCTCC NO: M20252780. The 16S rDNA (ribosomal deoxyribonucleic acid) sequence of the strain is as shown in SEQ ID NO. 1. The bacillus cereus Sys-Gs-004 strain provided by the invention can produce ginsenoside Rh2 through metabolism, can be subjected to large-scale fermentation culture in a short time, is relatively low in fermentation cost, is not limited by conditions such as time domain and season, and has remarkable advantages. Meanwhile, the invention also provides optimized microbial fermentation conditions and a formula of the culture medium, and the yield of the ginsenoside Rh2 is relatively high.